Cardiff Oncology, Inc. (NASDAQ:CRDF) Short Interest Up 7.2% in October

Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 7,320,000 shares, a growth of 7.2% from the September 30th total of 6,830,000 shares. Based on an average daily trading volume, of 495,200 shares, the short-interest ratio is presently 14.8 days.

Institutional Investors Weigh In On Cardiff Oncology

A number of institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in shares of Cardiff Oncology during the 3rd quarter worth approximately $64,000. Point72 DIFC Ltd acquired a new position in shares of Cardiff Oncology in the second quarter valued at $27,000. Cubist Systematic Strategies LLC increased its holdings in shares of Cardiff Oncology by 112.9% in the second quarter. Cubist Systematic Strategies LLC now owns 68,730 shares of the company's stock valued at $153,000 after purchasing an additional 36,441 shares during the last quarter. Invst LLC bought a new position in shares of Cardiff Oncology in the second quarter valued at about $74,000. Finally, XTX Topco Ltd acquired a new stake in shares of Cardiff Oncology during the 2nd quarter worth about $185,000. 16.29% of the stock is owned by institutional investors.

Cardiff Oncology Trading Up 2.7 %

Shares of NASDAQ:CRDF traded up $0.08 during trading on Friday, hitting $3.21. 683,597 shares of the company were exchanged, compared to its average volume of 930,371. Cardiff Oncology has a fifty-two week low of $0.94 and a fifty-two week high of $6.42. The stock has a market cap of $149.19 million, a price-to-earnings ratio of -3.52 and a beta of 1.96. The firm has a fifty day moving average price of $2.61 and a two-hundred day moving average price of $2.80.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.01). Cardiff Oncology had a negative return on equity of 62.65% and a negative net margin of 6,143.91%. The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.12 million. During the same period last year, the company posted ($0.25) earnings per share. As a group, research analysts predict that Cardiff Oncology will post -1 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum began coverage on shares of Cardiff Oncology in a research note on Friday, September 6th. They set a "buy" rating and a $8.00 price objective for the company.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.